Goldman Sachs downgraded Merck to Buy from Conviction Buy as part of the firm’s “US Conviction List – Directors’ Cut” for March. Goldman removed Apple (AAPL), Merck (MRK), and Vertex Pharmaceuticals (VRTX) from its Conviction List.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MRK:
- Merck receives positive EU CHMP opinion for KEYTRUDA
- NY AG James urges stricter warnings for Merck’s Singulair
- Evaxion announces completion of initial phases of collaboration with MSD
- Merck: FDA grants priority review to sBLA for Keytruda plus chemotherapy
- Merus price target raised to $56 from $48 at Guggenheim
